The SMB Pharmacometrics Subgroup is excited to be launching our webinar series next Tuesday, September 9, 12:00-1:00pm ET. Our speaker will be Malidi Ahamadi, Head of Modeling & Simulation within Quantitative Pharmacology at Sanofi. To receive the Zoom meeting information, please RSVP via this form.

Title: Model-Informed Drug Development: Scientific Frontiers and Career Pathways in Pharmacometrics
Abstract: Model-Informed Drug Development (MIDD) has become a cornerstone of modern drug development, enabling more efficient and scientifically rigorous decision-making across discovery, development, and regulatory interactions. In this talk, I will highlight recent advances in MIDD, including applications in oncology, neuroscience, and emerging AI/ML approaches, as well as the global harmonization efforts reflected in the ICH M15 draft guidance. Alongside the scientific content, I will share insights from my own career journey—beginning in applied mathematics and progressing through academia, regulatory collaborations, and leadership in industry—to illustrate the diverse pathways available to early-career scientists in pharmacometrics. Emphasis will be placed on developing core skills, building interdisciplinary collaborations, and engaging with professional societies to grow as both scientists and leaders. The session will conclude with practical advice for navigating a career in pharmacometrics and a discussion of future opportunities for the field.

Malidi Ahamadi, PhD, is Head of Modeling & Simulation within Quantitative Pharmacology at Sanofi, where he oversees global M&S strategies spanning early development to lifecycle management. He has over 20 years of experience in quantitative sciences, with a career that bridges applied mathematics, academia, and pharmaceutical drug development. Dr. Ahamadi has played a leading role in advancing Model-Informed Drug Development (MIDD) initiatives, serving as Deputy Topic Lead and co-author of the recent ICH M15 draft guidance on general principles for MIDD. He has contributed extensively to regulatory and industry collaborations, including the FDA MIDD Paired Meeting Program, the Clinical Trials Transformation Initiative, and the Critical Path Institute’s Parkinson’s disease consortium. Beyond his scientific and regulatory leadership, Dr. Ahamadi is deeply committed to mentoring junior scientists and fostering interdisciplinary connections, serving on the Mathematical and Computational Sciences SIG Steering Committee and active member of Pharmacometrics Subgroup of the Society for Mathematical Biology.